^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Adenocarcinoma
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The following regimens recommended added as Other Recommended for adenocarcinoma, large cell, NSCLC NOS….Cemiplimab-rwlc + paclitaxel + (carboplatin or cisplatin) (category 1)…Cemiplimab-rwlc + pemetrexed + (carboplatin or cisplatin) (category 1)
    Secondary therapy:
    carboplatin + paclitaxel; cisplatin + pemetrexed; cisplatin + paclitaxel; carboplatin + pemetrexed